Please ensure Javascript is enabled for purposes of website accessibility

Why Ardelyx Stock Soared Today

By Keith Speights - Updated Apr 14, 2021 at 3:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's Japanese partner initiated pivotal late-stage studies of Ardelyx's lead candidate.

What happened

Shares of Ardelyx (ARDX -0.94%) were soaring 8.9% as of 2:57 p.m. EDT on Wednesday. The big jump came after the company announced that its Japanese partner, Kyowa Kirin, has begun four late-stage clinical studies evaluating Ardelyx's lead candidate tenapanor in treating hyperphosphatemia, a disorder where there's an abnormally high level of phosphate in the blood.

So what

Kyowa Kirin's initiation of multiple phase 3 studies is good news for Ardelyx in a couple of ways. For one thing, it triggered a $5 million milestone payment. More importantly, it gets the two collaboration partners even closer to potential regulatory approval for tenapanor in Japan.

Scientist looking through a microscope

Image source: Getty Images.

Ardelyx received a $30 million up-front payment from Kyowa Kirin in 2017 when the Japanese drugmaker licensed tenapanor, and it stands to receive a total of up to $55 million in development milestone payments plus up to 8.5 billion yen (around $78 million based on current exchange rates) in commercialization milestones. Ardelyx will also receive royalties in the high teens if tenapanor wins approval in Japan.

Now what

While the start of Japanese clinical studies is good news for Ardelyx, a more important milestone for the biotech stock is only a couple of weeks away. By April 29, the Food and Drug Administration should announce its approval decision for tenapanor in controlling phosphorus levels in adult patients with chronic kidney disease.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ardelyx, Inc. Stock Quote
Ardelyx, Inc.
ARDX
$1.05 (-0.94%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.